<?xml version='1.0' encoding='utf-8'?>
<document id="32202190"><sentence text="Effects of naringenin on the pharmacokinetics of tofacitinib in rats."><entity charOffset="11-21" id="DDI-PubMed.32202190.s1.e0" text="naringenin" /><entity charOffset="49-60" id="DDI-PubMed.32202190.s1.e1" text="tofacitinib" /><pair ddi="false" e1="DDI-PubMed.32202190.s1.e0" e2="DDI-PubMed.32202190.s1.e0" /><pair ddi="false" e1="DDI-PubMed.32202190.s1.e0" e2="DDI-PubMed.32202190.s1.e1" /></sentence><sentence text="Context: Naringenin and tofacitinib are often used together for treatment of rheumatoid arthritis in Chinese clinics"><entity charOffset="9-19" id="DDI-PubMed.32202190.s2.e0" text="Naringenin" /><entity charOffset="24-35" id="DDI-PubMed.32202190.s2.e1" text="tofacitinib" /><pair ddi="false" e1="DDI-PubMed.32202190.s2.e0" e2="DDI-PubMed.32202190.s2.e0" /><pair ddi="false" e1="DDI-PubMed.32202190.s2.e0" e2="DDI-PubMed.32202190.s2.e1" /></sentence><sentence text="Objective: This experiment investigates the effect of naringenin on the pharmacokinetics of tofacitinib in rats"><entity charOffset="54-64" id="DDI-PubMed.32202190.s3.e0" text="naringenin" /><entity charOffset="92-103" id="DDI-PubMed.32202190.s3.e1" text="tofacitinib" /><pair ddi="false" e1="DDI-PubMed.32202190.s3.e0" e2="DDI-PubMed.32202190.s3.e0" /><pair ddi="false" e1="DDI-PubMed.32202190.s3.e0" e2="DDI-PubMed.32202190.s3.e1" /></sentence><sentence text="Materials and methods: Twelve Sprague-Dawley rats were randomly divided into two groups (experimental group and control group)" /><sentence text=" The experimental group was pre-treated with naringenin (150 mg/kg/day) for two weeks before dosing tofacitinib, and equal amounts of CMC-Na solution in the control group"><entity charOffset="45-55" id="DDI-PubMed.32202190.s5.e0" text="naringenin" /><entity charOffset="100-111" id="DDI-PubMed.32202190.s5.e1" text="tofacitinib" /><pair ddi="false" e1="DDI-PubMed.32202190.s5.e0" e2="DDI-PubMed.32202190.s5.e0" /><pair ddi="false" e1="DDI-PubMed.32202190.s5.e0" e2="DDI-PubMed.32202190.s5.e1" /></sentence><sentence text=" After a single oral administration of 5 mg/kg of tofacitinib, 50 μL blood samples were directly collected into 1"><entity charOffset="50-61" id="DDI-PubMed.32202190.s6.e0" text="tofacitinib" /></sentence><sentence text="5 mL heparinized tubes via the caudal vein at 0" /><sentence text="083, 0" /><sentence text="5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 h" /><sentence text=" The plasma concentration of tofacitinib was quantified by UPLC/MS-MS"><entity charOffset="29-40" id="DDI-PubMed.32202190.s10.e0" text="tofacitinib" /></sentence><sentence text="Results: Results indicated that naringenin could significantly affect the pharmacokinetics of tofacitinib"><entity charOffset="32-42" id="DDI-PubMed.32202190.s11.e0" text="naringenin" /><entity charOffset="94-105" id="DDI-PubMed.32202190.s11.e1" text="tofacitinib" /><pair ddi="false" e1="DDI-PubMed.32202190.s11.e0" e2="DDI-PubMed.32202190.s11.e0" /><pair ddi="false" e1="DDI-PubMed.32202190.s11.e0" e2="DDI-PubMed.32202190.s11.e1" /></sentence><sentence text=" The AUC0-24 of tofacitinib was increased from 1222"><entity charOffset="16-27" id="DDI-PubMed.32202190.s12.e0" text="tofacitinib" /></sentence><sentence text="81 ± 222" /><sentence text="07 to 2016" /><sentence text="27 ± 481" /><sentence text="62 ng/mL/h, and the difference was significant (p &lt; 0" /><sentence text="05)" /><sentence text=" Compared with the control group, the Tmax was increased from 0" /><sentence text="75 ± 0" /><sentence text="29 to 3" /><sentence text="00 ± 0" /><sentence text="00 h (p &lt; 0" /><sentence text="05), and the MRT(0-24) was increased from 4" /><sentence text="90 ± 0" /><sentence text="51 to 6" /><sentence text="57 ± 0" /><sentence text="66 h (p &lt; 0" /><sentence text="05), but the clearance was obviously decreased from 4" /><sentence text="10 ± 0" /><sentence text="72 to 2" /><sentence text="42 ± 0" /><sentence text="70 L/h/kg (p &lt; 0" /><sentence text="05) in experimental group" /><sentence text=" Although the Cmax and t1/2 of tofacitinib were increased, there were no significant differences (p &gt; 0"><entity charOffset="31-42" id="DDI-PubMed.32202190.s34.e0" text="tofacitinib" /></sentence><sentence text="05)" /><sentence text="Conclusions: This research demonstrated a drug-drug interaction between naringenin and tofacitinib possibly when preadministered with naringenin; thus, we should pay attention to this possibility in the clinic"><entity charOffset="72-82" id="DDI-PubMed.32202190.s36.e0" text="naringenin" /><entity charOffset="87-98" id="DDI-PubMed.32202190.s36.e1" text="tofacitinib" /><entity charOffset="134-144" id="DDI-PubMed.32202190.s36.e2" text="naringenin" /><pair ddi="false" e1="DDI-PubMed.32202190.s36.e0" e2="DDI-PubMed.32202190.s36.e0" /><pair ddi="false" e1="DDI-PubMed.32202190.s36.e0" e2="DDI-PubMed.32202190.s36.e1" /><pair ddi="false" e1="DDI-PubMed.32202190.s36.e0" e2="DDI-PubMed.32202190.s36.e2" /><pair ddi="false" e1="DDI-PubMed.32202190.s36.e1" e2="DDI-PubMed.32202190.s36.e1" /><pair ddi="false" e1="DDI-PubMed.32202190.s36.e1" e2="DDI-PubMed.32202190.s36.e2" /></sentence><sentence text="" /></document>